GI-101

N/A

Report date: 2026/04/03 20:03:44

Base Information

Drug NameGI-101
Drug Alias Namebi-specific fragment crystallizable region (Fc) fusion protein containing cluster of differentiation 80 ectodomain as an N-terminal moiety and interleukin-2 variant as a C-terminal moiety conjugated with human immunoglobulin G4 FcGI-101SIM-323SIM323SIM0323
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitorsInterleukin-2 receptor beta chain agonistsInterleukin-2 receptor subunit gamma agonists +[4] 
TargetsCytotoxic T-Lymphocyte-Associated Antigen 4Interleukin-2 receptor beta chainInterleukin-2 receptor subunit gamma +[4] 
Therapy Area/IndicationsSolid tumoursUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell Lung +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth Korea
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesGI Innovation Inc
China Registration ClassN/A

Develop Information

Active CompaniesSimcere Pharmaceutical Group LtdGI Innovation Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell Lung +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A